English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Baseline data were utilized from a double‐blind, randomized, placebo‐controlled trial (G300203) that was designed to determine the capacity of toremifene (a second‐generation selective estrogen receptor modulator) to prevent bone fractures in men on ADT. This study included 1389 men from 150 sites in the US and Mexico. Patients were randomized in the ratio of 1:1 to receive toremifene 80 mg by mouth daily or matched placebo. Results from the primary analysis have already been published.4 Baseline characteristics, including whether men were on medical ADT or status postorchiectomy, were available. The primary objective of this study is to describe baseline hormone levels in men receiving medical ADT or who underwent orchiectomy before initiating toremifene. Hormone levels were determined in a centralized clinical testing facility utilizing an Food and Drug Administration‐approved radioimmunoassay (RIA) (Diagnostic Products Corporation, Los Angeles, CA, USA). Free testosterone levels were estimated using RIA and equilibrium dialysis as previously described.5 We also evaluated for differences in hormone levels between groups using the Wilcoxon rank‐sum test. This study was conducted in accordance with the Declaration of Helsinki and was approved by the local ethics committees of the participating institutions. Informed written consent was obtained from all patients before their enrollment in this study. Between November 2003 and October 2005, 1284 men with prostate cancer receiving ADT were randomized between placebo and toremifene. Of this cohort, castrating therapy was administered as follows: 1191 received an LHRH agonist, 56 underwent bilateral orchiectomy, 27 underwent bilateral orchiectomy with androgen receptor blockade, and 10 underwent bilateral orchiectomy and also received an LHRH agonist. Details for why ten patients received LHRH agonist therapy and orchiectomy are not available as these data were gleaned from case report forms which are no longer available for review. LH levels were significantly lower and estradiol levels were significantly higher in men receiving LHRH agonist therapy. There was no significant difference in total or free T levels between groups (Table 1). However, there was less variability in total and free T levels in orchiectomized patients compared to those receiving LHRH agonists. For instance, the total T ranged from 0.69 ng dl−1 to 29.5 ng dl−1 in men receiving LHRH agonist therapy alone compared to 0.69 ng dl−1 to 13.01 ng dl−1 in patients who underwent orchiectomy. To our knowledge, this study is the largest to report free T levels in men who underwent orchiectomy. In this cohort, the mean serum‐free Dear Editor, In the 1940s, Charles Huggins discovered that surgical castration produced remarkable palliative benefits for men with advanced prostate cancer, an effect we now understand to be mediated through depriving the androgen receptor (AR) from its ligands (i.e., testicular‐derived androgens). In the years since, medical forms of androgen deprivation therapy (ADT) have largely replaced orchiectomy as the predominate means of achieving castrate testosterone (T) levels, and currently, luteinizing hormone‐releasing hormone (LHRH) agonists (e.g., leuprolide) are the most common form of ADT. Importantly, studies have shown that LHRH agonists are clinically efficacious and, similar to surgical castration, drive T below 50 ng dl−1 for most patients.1 While T <50 ng dl−1 is the most frequently cited definition for what constitutes a castrate level T, it should be recognized that multiple studies have demonstrated better outcomes with lower T levels. For instance, Klotz et al.2 reported that, in patients enrolled to the Phase III PR‐7 study testing intermittent versus continuous ADT in nonmetastatic biochemically recurrent prostate cancer patients, a total T level <20 ng dl−1 was associated with improved disease‐specific survival and time‐to‐castration resistance compared those with a total T level >20 ng dl−1. This observation has led to the European Association of Urology to recommend that a level of <20 ng dl−1 should be used to define a castrate level of T. It is important to note that the total serum T levels include both free and protein‐bound (e.g., sex hormone‐binding globulin, albumin) fractions, while older studies have shown that LHRH agonists suppress total T levels below castrate levels; it is widely understood that free, or unbound, T is the biologically and clinically relevant component.3 That being the case, the therapeutic goal of medical ADT should be to decrease free T levels to those achieved with orchiectomy. However, to date, free T has not been well studied in large cohorts of orchiectomized men. The purpose of this study was to examine total T and free T levels in men who have undergone orchiectomy or received medical ADT in the context of a prospective clinical trial. These determinations will help set expectations for future development of novel agents that effect androgen levels. LETTER TO THE EDITOR

Hormone levels following surgical and medical castration: defining optimal androgen suppression